Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4ZDOE)

Drug Name

DpC Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Iron (Fe)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Etidronate Disodium	DMAWJIN	Osteoporosis	FB83.0	Approved	[3]
Deferiprone	DMS2M7O	Beta thalassemia	3A50.2	Approved	[4]
Deferoxamine Mesylate	DMTUKZH	Acute iron or aluminum toxicity	FB83.20	Approved	[3]
Exjade	DMHPRWG	Iron overload disease	5C64.10	Approved	[5]
Soluble ferric pyrophosphate	DMLAYTP	Iron-deficiency anemia	3A00	Phase 3	[6]
SPD602	DMKJ9LU	Anemia	3A00-3A9Z	Phase 2	[7]
Monohydroxyethylrutoside	DMAQJHO	Cardiovascular disease	BA00-BE2Z	Phase 1	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT02688101) Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
2	Anticancer Thiosemicarbazones: Chemical Properties, Interaction with Iron Metabolism, and Resistance Development. Antioxid Redox Signal. 2019 Mar 10;30(8):1062-1082.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
5	Deferasirox : a review of its use in the management of transfusional chronic iron overload. Drugs. 2007;67(15):2211-30.
6	A micronised, dispersible ferric pyrophosphate with high relative bioavailability in man. Br J Nutr. 2004 Jan;91(1):107-12.
7	ClinicalTrials.gov (NCT01604941) Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy. U.S. National Institutes of Health.
8	Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin. Clin Cancer Res. 1997 Oct;3(10):1747-54.